

| Botulinum toxin | Botox (ona) | Dysport (abo) | Xeomin (inco) | Myobloc (rima) |
|--|------------------|------------------------|--------------------|---|
| Botulinum toxin type | A | A | A | B |
| Biologic activity in relation to Botox | 1 | 1/3 | 1 | 1/40 |
| <i>C. botulinum</i> strain | Hall A | Ipsen strain | Hall A | Bean B |
| Excipients (human serum albumin) | 500 µg/vial | 125 µg/vial | 1 mg/vial | 0.5 mg/cc |
| Stabilizer | NaCl 900 µg/vial | Lactulose 2500 µg/vial | Sucrose 4.7mg/vial | Disodium succinate 0.01 M, H2O, hydrochloric acid |

| Botulinum toxin | Botox (ona) | Dysport (abo) | Xeomin (inco) | Myobloc (rima) |
|---|---|---|----------------------|---|
| Protein and toxin (100 kDa heavy chain and 50kDa light chain) configuration | 300 300 50 50 100 100 900 | 300 300 50 50 100 100 900 | 150 50 100 | 150 150 50 50 100 100 600 |
| SNARE target | SNAP25 | SNAP25 | SNAP25 | VAMP |
| Biologic activity | 100 MU-A/vial | 500 MU-I/vial | 100 MU-M/vial | 1.0/2.5/10/0kMU-E/vial |
| preparation | powder | powder | powder | solution |
| storage | <8°C | <8°C | <25°C | <8°C |
| Shelf life (months) | 36 | 24 | 36 | 24 |
| Manufacture | Allergan | Ipsen | Merz | Solice |